S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
NASDAQ:CEMI

Chembio Diagnostics - CEMI Stock Forecast, Price & News

$0.39
+0.01 (+2.63%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.38
$0.40
50-Day Range
$0.33
$0.45
52-Week Range
$0.19
$1.24
Volume
529,058 shs
Average Volume
550,037 shs
Market Capitalization
$14.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CEMI stock logo

About Chembio Diagnostics (NASDAQ:CEMI) Stock

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
CEMI Chembio Diagnostics, Inc.
Chembio Diagnostics
Chembio Expands Distribution
See More Headlines
Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Company Calendar

Last Earnings
11/04/2021
Today
3/25/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CEMI
Employees
337
Year Founded
N/A

Profitability

Net Income
$-33,900,000.00
Pretax Margin
-60.91%

Debt

Sales & Book Value

Annual Sales
$47.82 million
Book Value
$1.14 per share

Miscellaneous

Free Float
35,497,000
Market Cap
$14.32 million
Optionable
Not Optionable
Beta
1.83

Key Executives

  • Richard L. Eberly
    President, Chief Executive Officer & Director
  • Paul J. Angelico
    Chief Operations Officer & Executive VP
  • Lawrence J. Steenvoorden
    Chief Financial Officer, Secretary & Executive VP
  • Javan Esfandiari
    Executive VP, Chief Science & Technology Officer
  • Paul Lambotte
    Vice President-Research & Development













CEMI Stock - Frequently Asked Questions

How have CEMI shares performed in 2023?

Chembio Diagnostics' stock was trading at $0.2197 at the start of the year. Since then, CEMI shares have increased by 77.5% and is now trading at $0.39.
View the best growth stocks for 2023 here
.

When is Chembio Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our CEMI earnings forecast
.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.05. The company had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative net margin of 60.93% and a negative trailing twelve-month return on equity of 129.14%. During the same period in the prior year, the company earned ($0.28) earnings per share.

What other stocks do shareholders of Chembio Diagnostics own?
What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $0.39.

How much money does Chembio Diagnostics make?

Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $14.32 million and generates $47.82 million in revenue each year. The company earns $-33,900,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Chembio Diagnostics have?

The company employs 337 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065.

This page (NASDAQ:CEMI) was last updated on 3/25/2023 by MarketBeat.com Staff